Literature DB >> 2914105

Susceptibility testing of Danish isolates of Capnocytophaga and CDC group DF-2 bacteria.

A Bremmelgaard1, C Pers, J E Kristiansen, B Korner, O Heltberg, W Frederiksen.   

Abstract

Twelve Capnocytophaga and seven DF-2 strains were tested for their susceptibility to 14 antimicrobial agents using an agar dilution and an agar diffusion method. Twenty-three other antibiotics were evaluated using the diffusion test only. All strains were fully susceptible to penicillin, ampicillin, cefuroxime, cefotaxime, erythromycin, clindamycin, chloramphenicol, doxycycline, rifamycin and ofloxacin using both methods. Clindamycin, rifamycin and cefotaxime were most active. Using agar dilution some strains were susceptible to gentamicin, but agar diffusion showed total resistance. One Capnocytophaga strain was susceptible and another moderately susceptible to metronidazole, other strains were resistant. The agar diffusion test showed that both Capnocytophaga and DF-2 were resistant to most other aminoglycosides, to fosfomycin, polymyxin and trimethoprim. All strains of both taxa were fully susceptible to piperacillin, cefoxitin, imipenem and fusidic acid and showed different susceptibilities to the other agents. Susceptibility testing by means of agar diffusion using an enriched chocolate agar and 5% CO2 atmosphere could be used to test Capnocytophaga and DF-2 strains and gives sufficient accuracy for routine use, when revised inhibition zone breakpoints are employed.

Entities:  

Mesh:

Year:  1989        PMID: 2914105     DOI: 10.1111/j.1699-0463.1989.tb00753.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  15 in total

1.  Antimicrobial susceptibilities and beta-lactamase characterization of Capnocytophaga species.

Authors:  D L Roscoe; S J Zemcov; D Thornber; R Wise; A M Clarke
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

2.  Capnocytophaga cynodegmi cellulitis, bacteremia, and pneumonitis in a diabetic man.

Authors:  P S Sarma; S Mohanty
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

Review 3.  Capnocytophaga canimorsus infections in human: review of the literature and cases report.

Authors:  C Lion; F Escande; J C Burdin
Journal:  Eur J Epidemiol       Date:  1996-10       Impact factor: 8.082

4.  Antimicrobial susceptibility of Capnocytophaga spp.

Authors:  A Verghese; B Franzus; S Berk; D L Roscoe; A M Clarke
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

5.  A Common Molecular Switch for H2S to Regulate Multiple Protein Targets.

Authors:  Bei-Bei Tao; Yi-Chun Zhu
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Capnocytophaga cynodegmi peritonitis in a peritoneal dialysis patient.

Authors:  Charlotte Pers; Erling Tvedegaard; Jens Jørgen Christensen; Jette Bangsborg
Journal:  J Clin Microbiol       Date:  2007-09-19       Impact factor: 5.948

7.  Molecular basis for receptor tyrosine kinase A-loop tyrosine transphosphorylation.

Authors:  Lingfeng Chen; William M Marsiglia; Huaibin Chen; Joseph Katigbak; Hediye Erdjument-Bromage; David J Kemble; Lili Fu; Jinghong Ma; Gongqin Sun; Yingkai Zhang; Guang Liang; Thomas A Neubert; Xiaokun Li; Nathaniel J Traaseth; Moosa Mohammadi
Journal:  Nat Chem Biol       Date:  2020-01-20       Impact factor: 15.040

8.  Preparation and identification of an anti-idiotypic antibody antagonist (FG8) for EGFR that shows potential activity against liver cancer cells.

Authors:  Yurong Wang; Fangping He; Helin Zhang; Ying Cao; Yaqing Zhang; Yun Ling; Aliya Rehati
Journal:  Biotechnol Lett       Date:  2020-11-03       Impact factor: 2.461

9.  Prevalence of oropharyngeal beta-lactamase-producing Capnocytophaga spp. in pediatric oncology patients over a ten-year period.

Authors:  Anne Jolivet-Gougeon; Zohreh Tamanai-Shacoori; Laurent Desbordes; Virginie Gandemer; Jean-Louis Sixou; Nolwenn Morvan-Graveline; Michel Cormier; Martine Bonnaure-Mallet
Journal:  BMC Infect Dis       Date:  2005-05-09       Impact factor: 3.090

Review 10.  Receptor Tyrosine Kinases as Therapeutic Targets for Alcohol Use Disorder.

Authors:  Kana Hamada; Amy W Lasek
Journal:  Neurotherapeutics       Date:  2020-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.